TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentato sab 29 ago · 08:15 CESTHot Line 2Tutti gli studi Hot Line →

STAREE

2026

STAtin Therapy for Reducing Events in the Elderly

In 9,971 healthy adults aged 70 years or over, atorvastatin 40 mg improved one of two co-primary outcomes disability-free survival and major cardiovascular events compared with placebo.

Risultato

Efficacia: Co-primary: (1) disability-free survival, defined as survival free of dementia and persistent physical disability; (2) major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or stroke; registry definition also lists coronary revascularisation)HR 0,70 (IC 95% 0,61-0,82) · P < 0,001

Sotto 1 a favore di atorvastatin 40 mg, sopra 1 a favore di placebo.

Tassi di eventi
Differenza assoluta
2,3 punti
NNT
44

La differenza assoluta e l’NNT sono derivati dai tassi di eventi.

Riportato inoltre: The other co-primary, disability-free survival, was unchanged: 12.8% vs 13.6% (HR 0.94, 95% CI 0.84-1.05; P = 0.25). Muscle, liver and diabetes-related adverse events were more common with atorvastatin; serious adverse events 2.7% in both arms.

Pubblicazione originale
Sottotema
Primary prevention
Disegno
Double-blind, placebo-controlled RCT, 1:1, recruited through Australian general practice, average follow-up about 6 years planned, time-to-first-event analyses for each co-primary endpoint
Rilevanza
Definisce la pratica: uno studio imprescindibile nella disciplina.
Fonte
Zoungas S, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607314

Discussione e critica

The trial general practice has been waiting for: a statin started after 70, in people without cardiovascular disease, diabetes or dementia. Cardiovascular events fall by 30% relative and 2.3 percentage points absolute over six years, roughly 43 people treated for one event avoided. The endpoint older patients are usually promised, years free of dementia and disability, did not move, and the entrants were healthy volunteers rather than the frail, comorbid 80-year-olds in whom the question is hardest.

Discusso nei podcast